Trulicity Injection, Solution
Product Images NDC 50090-7589

Product Visual Gallery

This gallery contains 50 technical images submitted to the FDA as part of the official labeling for Trulicity (NDC 50090-7589). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907589)

TRULICITY 4.5 mg/0.5 mL injection solution label from A-S Medication Solutions. The label states the product name, active ingredient Dulaglutide, strength, dosage form, and includes directions for storage and use in single-dose pens. It also displays the product NDC 50090-7589-0 and distributor information from A-S Medication Solutions in Libertyville, Illinois.*

FDA Label Image

Logo (Logo)

FDA Label Image

Qr Code (Qr V1)

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Back V1)

An anatomical line drawing of a human figure from behind, highlighting both upper arm areas in yellow to indicate sites for subcutaneous injection. The illustration demonstrates appropriate injection locations on the left and right upper arms.*

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Front V1)

An illustration showing a human figure highlighting recommended subcutaneous injection sites. The highlighted areas in yellow include the abdomen around the navel and the front middle sections of both thighs. No additional text or labels are visible.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Back V1)

Illustration showing recommended injection sites for a subcutaneous injection, highlighting the upper arms on both sides of a human figure in blue.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Front V1)

An illustration showing recommended subcutaneous injection sites on a human figure. The highlighted areas include the abdomen around the navel and the front of both thighs, indicating appropriate injection sites for the medication.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites Back V1)

Illustration showing the back view of a human figure with highlighted areas on the upper arms, indicating possible injection sites for subcutaneous administration of medication such as Trulicity (Dulaglutide) injection.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites Front V1)

An instructional illustration showing an outline of a human torso with shaded areas indicating recommended subcutaneous injection sites. The marked areas include the abdomen around the navel and the front and upper outer portions of both thighs.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites Back V1)

An instructional diagram illustrating potential subcutaneous injection sites on the human body. Highlighted areas include the upper outer regions of both arms, indicating suitable locations for administering a subcutaneous injection.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites Front V1)

Illustration showing recommended injection sites on a human body for subcutaneous administration. The diagram highlights the abdomen around the navel and the front thighs as suitable areas for injection.*

FDA Label Image

Figure (Trulicity Ifu Check V1)

FDA Label Image

Exclamation (Trulicity Ifu Exclamation V1)

TRULICITY 4.5 mg/0.5 mL injection in solution, a subcutaneous injection product by A-S Medication Solutions. The image shows a white pen injector with yellow labeling and a green cap on the needle end.*

FDA Label Image

Figure (Trulicity Ifu Expiration Location V2)

An illustration showing the location of the expiration date on a prefilled syringe. The syringe is labeled with the medication name TRULICITY and the expiration date area is highlighted with an arrow pointing to a black box on the syringe barrel where the date is printed.*

FDA Label Image

Figure (Trulicity Ifu Inspect V1)

FDA Label Image

Locked (Trulicity Ifu Locked V1)

The image shows a vial and its carton packaging for TRULICITY 4.5 mg/.5 mL injection, solution for subcutaneous use. The label displays the product name TRULICITY with the generic name Dulaglutide, provided by the labeler A-S Medication Solutions, including the NDC 50090-7589. The vial contains 0.5 mL of solution.*

FDA Label Image

Figure (Trulicity Ifu Prepare V1)

FDA Label Image

Figure (Trulicity Ifu Remove V1)

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F2 V3)

An instructional illustration showing two hands preparing a prefilled injectable pen. The top hand holds the pen vertically, while the bottom hand removes a black plastic cap from the bottom of the pen. A downward purple arrow indicates the direction of the cap removal action.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F3 V3)

An instructional illustration showing a person holding a green-capped injection pen, preparing for subcutaneous injection. The individual is applying a purple safety cap removal step while positioning the pen near the abdomen area, indicating proper handling technique for an injectable medication.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F4 V3)

An instructional illustration showing hands preparing a subcutaneous injection using a pen device, with a focus on waiting 5-10 seconds after injection. A zoomed-in inset highlights a detailed component of the pen tip, indicating an important step in injection preparation or completion.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F5 V3)

An instructional illustration showing a hand holding a prefilled syringe above a sharps disposal container with a biohazard symbol, demonstrating proper disposal of the injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen Parts V3)

An annotated diagram of a TRULICITY injection pen showing key parts including the injection button, lock ring, indicator, lock/unlock symbols, medicine reservoir, clear base, and base cap. The diagram labels the top and bottom (needle end) of the pen to illustrate the device components for subcutaneous injection use.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen V3)

The image shows a TRULICITY 4.5 mg/0.5 mL prefilled injection pen containing Dulaglutide solution for subcutaneous use. The pen is white with a yellow diagonal stripe and purple accents near the middle, a green cap at the right end, and a dark gray needle shield at the left end. The device is designed for single-use and self-administration.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F2 V3)

An instructional illustration showing a person's hands preparing a TRULICITY (Dulaglutide) injection pen. The illustration depicts the removal of a protective cap from the pen before injection, highlighting the proper handling technique.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F3 V3)

An instructional illustration showing hands preparing a prefilled injection pen, likely for subcutaneous administration. One hand holds the pen, with the other hand shown about to remove a green cap, indicating steps to ready the injection device for use.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F4 V3)

This instructional diagram shows a detailed step of preparing a subcutaneous injection using a prefilled syringe pen. It highlights a hand holding the injection pen against skin, with a timer indicating to hold the pen for 5 to 10 seconds. A close-up inset zooms in on the pen's dose window displaying the injection status.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F5 V3)

An instructional illustration showing a hand holding a used syringe above a biohazard sharps container, demonstrating proper disposal of the syringe after use. The container is marked with a biohazard symbol and has a lid to safely contain the syringe.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen Parts V3)

An instructional diagram illustrating parts of a prefilled injection pen device, including the Injection Button at the top, Lock Ring, Indicator with Lock/Unlock symbols, Medicine reservoir, Clear Base, and Base Cap at the bottom Needle End.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen V3)

TRULICITY 4.5 mg/0.5 mL injection, solution in a prefilled pen for subcutaneous use. The pen features a mostly white body with a blue section, green dose indicator, and a gray needle cover. The labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F2 V1)

An instructional illustration showing the use of a TRULICITY (dulaglutide) injection device. The image depicts one hand holding the injection pen and another hand preparing or removing a cap part below, with directional arrows and a safety lock symbol in red.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F3 V1)

Instructional illustration showing hands performing a step in administering a subcutaneous injection using a prefilled syringe or pen device. The image highlights a twisting or removal action of a green-capped needle cover, with a visual cue indicating to unlock or remove the cover before injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F4 V1)

Instructional diagram for administering a subcutaneous injection, showing a hand holding a syringe with the gray plunger visible. The image indicates to hold the injection for 5-10 seconds and notes that the injection is complete when the gray plunger is visible.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F5 V1)

Illustration showing a hand holding a syringe above a biohazard container, depicting proper disposal of a used injection device. This relates to the subcutaneous injection form of TRULICITY (dulaglutide) 4.5 mg/0.5 mL solution.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen Parts V1)

An instructional diagram of a TRULICITY injection pen showing labeled parts, including the injection button, lock ring, indicator, lock/unlock mechanism, medicine reservoir, clear base, and base cap. Arrows indicate the top (injection button) and bottom (needle end) of the pen.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen V1)

TRULICITY 4.5 mg/0.5 mL injection solution in a subcutaneous prefilled pen. The injection pen is primarily white with purple and green accents and a gray cap. The label includes brand and drug information, with a logo visible on the pen. Manufactured by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F2 V1)

An instructional illustration showing two hands handling a prefilled pen injector for subcutaneous injection. The top hand holds the pen device upright with a green button on top, while the bottom hand holds a black cap with a small nozzle, indicated to be pressed downward onto the pen device. This image likely demonstrates part of the preparation or injection process for the medication.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F3 V1)

An instructional illustration showing a person administering a subcutaneous injection in the abdominal area. The image depicts hands holding an injection pen with an arrow indicating a twisting motion to prepare or unlock the device, emphasizing proper injection technique.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F4 V1)

An instructional diagram showing how to administer a subcutaneous injection using a prefilled pen device. The image highlights holding the pen against the skin for 5 to 10 seconds and includes a close-up of the pen's gray plunger, indicating the injection is complete when the gray plunger is visible.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F5 V1)

An illustration showing a hand disposing of a syringe containing a solution into a biohazard sharps container. The syringe has a purple label band, and the container is marked with a biohazard symbol, indicating safe disposal of used injection devices.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen Parts V1)

Annotated diagram of a TRULICITY (dulaglutide) injection pen showing labeled parts including Injection Button, Lock Ring, Indicator, Lock/Unlock switch, Medicine compartment, Clear Base, and Base Cap. The orientation is marked from Top (injection button end) to Bottom (needle end).*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen V1)

TRULICITY 4.5 mg/0.5 mL injection solution in a prefilled single-dose pen for subcutaneous use. The pen has a white body with purple and green accents, a clear protective cap over the needle end, and is labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Unfold V1)

An instructional diagram showing an unfolded leaflet with a note to read both sides for full instructions. The illustration guides users to unfold and lay the leaflet flat to access the complete information.*

FDA Label Image

Unlocked (Trulicity Ifu Unlock V1)

TRULICITY 4.5 mg/0.5 mL injection, solution in a single-dose, prefilled subcutaneous pen. The box and pen feature the brand name TRULICITY prominently, with dosage strength listed. Container is labeled for single use and includes manufacturer details from A-S Medication Solutions. The design uses purple and white colors with dosage and usage instructions partially visible on the pen label.*

FDA Label Image

Figure 1 (Trulicity Pi F1 V2)

A pharmacokinetic forest plot chart illustrating the ratio and 90% confidence intervals for various intrinsic factors affecting drug exposure parameters AUC and Cmax for TRULICITY (dulaglutide). Factors analyzed include weight, age, sex, race, renal impairment, and hepatic impairment, with ratios relative to reference values shown on the x-axis.*

FDA Label Image

Figure 2 (Trulicity Pi F2 V2)

A forest plot chart showing the ratio and 90% confidence interval (CI) of pharmacokinetic (PK) parameters AUC and Cmax for various coadministered drugs relative to a reference. Drugs include Lisinopril, Metoprolol, Digoxin, Norelgestromin, Ethinylestradiol, Atorvastatin, Metformin, Acetaminophen, S-Warfarin, R-Warfarin, and Sitagliptin. The horizontal axis represents the ratio relative to reference ranging from 0.0 to 2.0.*

FDA Label Image

Figure 3 (Trulicity Pi F3 V3)

Line graph showing Least Squares Mean HbA1c percentage over 52 weeks post-randomization comparing four groups: TRULICITY 1.5 mg, TRULICITY 0.75 mg, Sitagliptin 100 mg, and placebo. The graph illustrates changes in HbA1c levels for each treatment group over time.*

FDA Label Image

Figure 4 (Trulicity Pi F4 V3)

A line graph depicting the mean HbA1c (%) over weeks post-randomization for TRULICITY injection, solution at strengths 1.5 mg, 3 mg, and 4.5 mg. Time points include baseline, 8, 12, 26, and 36 weeks, with separate curve lines for each dose level shown with distinct markers.*

FDA Label Image

Figure 5 (Trulicity Pi F5 V2)

A line graph showing least squares mean HbA1c (%) over 26 weeks post-randomization comparing TRULICITY 1.5 mg, TRULICITY 0.75 mg, Exenatide, and placebo groups. The graph plots HbA1c measurements at baseline, 13 weeks, and 26 weeks, illustrating trends for each treatment group.*

FDA Label Image

Figure 6 (Trulicity Pi F6 V2)

A line graph showing the percentage of patients with an event over time from randomization (up to 6 years). Two groups are compared: Dulaglutide and Placebo. The y-axis represents patients with an event (%), and the x-axis represents time (years). Dulaglutide shows a lower percentage of events compared to Placebo. Hazard ratio (HR) is 0.88 with a 95% confidence interval of 0.79 to 0.99.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.